Passive Biotech Equities

iShares Biotechnology ETF

The iShares Biotechnology ETF (the “Fund”) seeks to track the investment results of an index composed of U.S.-listed equities in the biotechnology sector.

$134.19

Compare similar ETFs

Fund Size
Dividend
Fees
Current
Biotechnology ETF IBB
Fund Size
$6.93 Billion
Dividend
0.3%
Fees
0.44%
Total Stock Market Index Fund VTI
Fund Size
$1.78 Trillion
Dividend
1.3%
Fees
0.03%
500 Index Fund VOO
Fund Size
$1.35 Trillion
Dividend
1.3%
Fees
0.03%
Core S&P 500 ETF IVV
Fund Size
$590 Billion
Dividend
1.4%
Fees
0.03%
Total International Stock Index Fund VXUS
Fund Size
$444 Billion
Dividend
3.1%
Fees
0.07%
View 1303 similar ETFs →

Average metrics of all companies in portfolio

Compare to
Market
Market Cap The market value of the company. It's calculated by multiplying the share price by the number of outstanding shares. $51.2 Billion
Dividend Yield Yearly payout to shareholders per share. The percentage indicates the payout in relation to the share price. 0.55 %
Beta Indicates the relationship between the price performance of a share and the market. 0.7449
P/E Ratio Ratio between share price and earnings per share. A low ratio could indicate that the stock is undervalued or investors aren't expecting high growth. A high ratio could indicate that the stock is overvalued or investors are expecting high growth. 100.94
Negative P/E Ratio a negative P/E ratio shows that the company is not profitable, and it shows how many years it would take the company to lose its entire market capitalisation if it did not change anything -89.13
Profitable Companies 51
PEG The ratio between the P/E ratio and the growth rate of the company's earnings per share in the last twelve months. A lower PEG could mean that a stock is undervalued. 17075.71
Price to Sales Ratio Market cap divided by the revenue in the most recent year. 9.83
Price to Book Ratio Price to Book Ratio is the Market cap divided by the Book value of the company 3.09
Compare to
Market
Enterprise Value to EBIT Enterprise Value divided by EBIT -45.55
Enterprise Value to Revenue Enterprise value divided by revenue 43.39
Total Debt to Enterprise Value Total debt divided by enterprise value 0.08
Debt to Equity A higher ratio indicates a higher risk. However, the ratio is difficult to compare between industries where common amounts of debt vary. NaN
Profit Margin Net income divided by revenue of the last 4 quarters. It indicates the company's profitability. -1973.21%
Quarterly Earnings Growth (YoY) The rate at which the company's net income has increased to the same quarter one year ago. -
Return on Equity Equity divided by market cap. -12.86%
Return on Assets Indicates a company's profitability in relation to its total assets. -0.38%
Return on Invested Capital Return on invested capital (ROIC) is net income after dividends divided by the sum of debt and equity. It shows how effective a company is at turning capital invested by shareholders and other debtholders into profits. -1.47%

Industries

Healthcare 81.8%
Other 10.8%
Materials 0.7%
Industrials 0.4%
N/A 6.3%

Market cap

Micro Cap 1%
Small Cap 8%
Mid Cap 21%
Large Cap 70%
Mega Cap 0%

269 Investments

P/E-Ratio
Total Investment
Weight
Gilead Sciences, Inc. logo

GILD - Manufacturing

Gilead Sciences, Inc.

P/E-Ratio
289.7
Total Investment
$554 Million
Weight
8.6%
Amgen, Inc. logo

AMGN - Manufacturing

Amgen, Inc.

P/E-Ratio
41.5
Total Investment
$512 Million
Weight
7.9%
Regeneron Pharmaceuticals, Inc. logo

REGN - Manufacturing

Regeneron Pharmaceuticals, Inc.

P/E-Ratio
16.3
Total Investment
$493 Million
Weight
7.6%
Vertex Pharmaceuticals, Inc. logo

VRTX - Manufacturing

Vertex Pharmaceuticals, Inc.

P/E-Ratio
-242.7
Total Investment
$478 Million
Weight
7.4%
BlackRock Funds III logo

BlackRock Funds III

P/E-Ratio
n/a
Total Investment
$466 Million
Weight
7.2%
IQVIA Holdings, Inc. logo

IQV - Health Care and Social Assistance

IQVIA Holdings, Inc.

P/E-Ratio
24.5
Total Investment
$231 Million
Weight
3.6%
Alnylam Pharmaceuticals, Inc. logo

ALNY - Manufacturing

Alnylam Pharmaceuticals, Inc.

P/E-Ratio
-111.8
Total Investment
$196 Million
Weight
3.0%
Argenx SE logo

ARGX - Manufacturing

Argenx SE

P/E-Ratio
-356.4
Total Investment
$188 Million
Weight
2.9%
Mettler-Toledo International, Inc. logo

MTD - Manufacturing

Mettler-Toledo International, Inc.

P/E-Ratio
30.0
Total Investment
$166 Million
Weight
2.6%
Biogen, Inc. logo

BIIB - Manufacturing

Biogen, Inc.

P/E-Ratio
12.4
Total Investment
$144 Million
Weight
2.2%
Waters Corp. logo

WAT - Manufacturing

Waters Corp.

P/E-Ratio
35.1
Total Investment
$144 Million
Weight
2.2%
BioNTech SE logo

BNTX - Manufacturing

BioNTech SE

P/E-Ratio
-32.0
Total Investment
$139 Million
Weight
2.2%
Illumina, Inc. logo

ILMN - Manufacturing

Illumina, Inc.

P/E-Ratio
-11.1
Total Investment
$137 Million
Weight
2.1%
Natera, Inc. logo

NTRA - Health Care and Social Assistance

Natera, Inc.

P/E-Ratio
-102.3
Total Investment
$128 Million
Weight
2.0%
United Therapeutics Corp. logo

UTHR - Manufacturing

United Therapeutics Corp.

P/E-Ratio
11.5
Total Investment
$101 Million
Weight
1.6%
Moderna, Inc. logo

MRNA - Manufacturing

Moderna, Inc.

P/E-Ratio
-3.7
Total Investment
$93.1 Million
Weight
1.4%
BeiGene Ltd. logo

BGNE - Manufacturing

BeiGene Ltd.

P/E-Ratio
-62.9
Total Investment
$91 Million
Weight
1.4%
Neurocrine Biosciences, Inc. logo

NBIX - Manufacturing

Neurocrine Biosciences, Inc.

P/E-Ratio
32.6
Total Investment
$87.8 Million
Weight
1.4%
Incyte Corp. logo

INCY - Professional, Scientific, and Technical Services

Incyte Corp.

P/E-Ratio
430.9
Total Investment
$85.5 Million
Weight
1.3%
BioMarin Pharmaceutical, Inc. logo

BMRN - Manufacturing

BioMarin Pharmaceutical, Inc.

P/E-Ratio
31.0
Total Investment
$80.7 Million
Weight
1.2%
Insmed, Inc. logo

INSM - Manufacturing

Insmed, Inc.

P/E-Ratio
-15.0
Total Investment
$78.6 Million
Weight
1.2%
Bio-Techne Corp. logo

TECH - Manufacturing

Bio-Techne Corp.

P/E-Ratio
62.3
Total Investment
$73.9 Million
Weight
1.1%
Genmab A/S logo

GMAB - Professional, Scientific, and Technical Services

Genmab A/S

P/E-Ratio
11.6
Total Investment
$70.9 Million
Weight
1.1%
Sarepta Therapeutics, Inc. logo

SRPT - Manufacturing

Sarepta Therapeutics, Inc.

P/E-Ratio
39.8
Total Investment
$70.6 Million
Weight
1.1%
Vaxcyte, Inc. logo

PCVX - Manufacturing

Vaxcyte, Inc.

P/E-Ratio
-19.7
Total Investment
$64.2 Million
Weight
1.0%